ScripNot quite two years after raising $175m in series C cash , inhaled respiratory therapy-focused Avalyn Pharma revealed on July 22 that it has raised a $100m series D round that CEO Lyn Baranowski said
Pink SheetGilead Sciences could learn this week whether the European Medicines Agency will recommend that lenacapavir should be approved for marketing as a twice-yearly preventative option for HIV in the EU as
ScripChinese biotechs are racing to push back the frontiers of combination therapies for antibody-drug conjugates (ADCs), progressing multiple assets into mid-stage clinical development. Beyond the validat
ScripAfter a rollercoaster six months which included a failed merger with Poolbeg Pharma and the sale of nearly all its assets to Gilead Sciences, Hookipa Pharma is pulling down the shutters. The Austrian